Cargando…

The Safety and Effectiveness of Infliximab Biosimilar in Managing Rheumatoid Arthritis: A Real-Life Experience from Jordan

BACKGROUND: Infliximab (IFX) biosimilar was the first biosimilar approved in Jordan in 2014, with limited evidence of its safety and effectiveness from the Middle East and North Africa (MENA) region. Thus, this study aimed to evaluate the safety and effectiveness of IFX biosimilar in active rheumato...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alawneh, Khaldoon, Al-Mistarehi, Abdel-Hameed, Qandeel, Ali, Jaber, Ruba, Alomari, Safwan, Kheirallah, Khalid A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439897/ https://www.ncbi.nlm.nih.gov/pubmed/36101813 http://dx.doi.org/10.1155/2022/3406783

Ejemplares similares

Prevalence of rheumatoid arthritis among hospital workers in the north of Jordan: Preliminary report of a hospital-based cohort study
por: Alawneh, Khaldoon M., et al.
Publicado: (2020)

The role of non-state actors in combating COVID-19 spread in Northern Jordan
por: Khassawneh, Adi H., et al.
Publicado: (2020)

Rheumatoid arthritis in Jordan: a cross sectional study of disease severity and associated comorbidities
por: Alawneh, Khaldoon M, et al.
Publicado: (2014)

Possible Modulation of Vascular Function Measures in Rheumatoid Arthritis by Homocysteine
por: Alomari, Mahmoud A., et al.
Publicado: (2018)

Ischemic stroke demographics, clinical features and scales and their correlations: an exploratory study from Jordan
por: Alawneh, Khaled Z, et al.
Publicado: (2022)

Domestic violence against women in Jordan: analysis of the demographic and health survey dataset 2017-2018
por: Kheirallah, Khalid Ahmed, et al.
Publicado: (2023)

Vascular Function and Handgrip Strength in Rheumatoid Arthritis Patients
por: Alomari, Mahmoud A., et al.
Publicado: (2012)

Prevalence estimates of drug addiction among high-school students and its association with violence, and school behaviors: A cross-sectional study from Jordan
por: Raffee, Liqaa A., et al.
Publicado: (2021)

The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses
por: Talotta, Rossella, et al.
Publicado: (2017)

Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison
por: Baji, Petra, et al.
Publicado: (2014)

Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis
por: Genovese, Mark C., et al.
Publicado: (2020)

Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany
por: Waller, John, et al.
Publicado: (2017)

Jordan’s Pandemic Influenza Preparedness (PIP): A Reflection on COVID-19 Response
por: Kheirallah, Khalid A., et al.
Publicado: (2022)

Efficacy of pillar implants to reduce snoring and daytime sleepiness
por: Khasawneh, Laith, et al.
Publicado: (2021)

Diaphragmatic Lipoma in a Woman with Rheumatoid Arthritis: A Case Report and Literature Review
por: Alawneh, Khaled Z., et al.
Publicado: (2020)

Anti-drug antibodies and rheumatoid factor level in patients with rheumatoid arthritis using the infliximab biosimilar CT-P13
por: Sakane, Hideo, et al.
Publicado: (2022)

Prioritizing zoonotic diseases utilizing the One Health approach: Jordan's experience
por: Kheirallah, Khalid A., et al.
Publicado: (2021)

Infliximab in the treatment of rheumatoid arthritis
por: Perdriger, A
Publicado: (2009)

Renal dysfunction among rheumatoid arthritis patients: A retrospective cohort study
por: Oweis, Ashraf O., et al.
Publicado: (2020)

RISK FACTORS FOR IN-HOSPITAL MORTALITY AMONG ADULTS HOSPITALIZED WITH COVID-19: A CROSS-SECTIONAL STUDY FROM JORDAN
por: AL-MISTAREHI, ABDEL-HAMEED, et al.
Publicado: (2022)

Determinants of the willingness of the general population to get vaccinated against COVID-19 in a developing country
por: Al-Mistarehi, Abdel-Hameed, et al.
Publicado: (2021)

A comparative study of PF‐06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis
por: Kameda, Hideto, et al.
Publicado: (2020)

Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis
por: Curtis, Jeffrey R., et al.
Publicado: (2019)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Medical students’ relative immunity, or lack thereof, against COVID-19 emotional distress and psychological challenges; a descriptive study from Jordan
por: Kheirallah, Khalid, et al.
Publicado: (2021)

Biosimilar infliximab use in paediatric IBD
por: Richmond, Lisa, et al.
Publicado: (2018)

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2019)

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries
por: Brodszky, Valentin, et al.
Publicado: (2014)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
por: Subedi, Smriti, et al.
Publicado: (2019)

SARS-CoV-2 Seroepidemiological Investigation in Jordan: Seroprevalence, Herd Immunity, and Vaccination Coverage. A Population-Based National Study
por: Sheikh Ali, Sami, et al.
Publicado: (2022)

A descriptive analysis of real-world treatment patterns of innovator (Remicade(®)) and biosimilar infliximab in an infliximab-naïve Turkish population
por: Yazici, Yusuf, et al.
Publicado: (2018)

Pattern of Uveitis in a Tertiary Hospital in North Jordan and the Impact of Behcet's Disease
por: Alawneh, Khaldoon M., et al.
Publicado: (2023)

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
por: Huizinga, Tom W. J., et al.
Publicado: (2020)

How does infliximab work in rheumatoid arthritis?
por: Maini, Ravinder N, et al.
Publicado: (2002)

PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy
por: Cohen, Stanley B., et al.
Publicado: (2018)

THE ADDED CLINICAL VALUE OF TOCILIZUMAB IN TREATING ADULTS HOSPITALIZED WITH COVID-19: A RETROSPECTIVE COHORT STUDY
por: AL-MISTAREHI, ABDEL-HAMEED, et al.
Publicado: (2022)

Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

Effects of Elemental Mercury Vapor Inhalation on Arterial Blood Gases, Lung Histology, and Interleukin-1 Expression in Pulmonary Tissues of Rats
por: Raffee, Liqaa A., et al.
Publicado: (2021)

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
por: Yoo, Dae Hyun, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nnib5oeqtj013ihg8fn1obkcqf